Yanhong Zhang

Yanhong Zhang

Auto-generated profile, based on publicly available information

Yanhong Zhang

Department of Neurology, School of Medicine, University of California, Davis, Davis, CA 95817, USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in Cell Reports
Verified
Journal Article
Open access
YWYan Wang
Yan Wang
YZYanhong Zhang
Yanhong Zhang
SZSheng Zhang
Sheng Zhang
BKBokyung Kim
Bokyung Kim
VHVanessa L. Hull
Vanessa L. Hull
FGFuzheng Guo
Fuzheng Guo
The function of poly(ADP-ribosyl) polymerase 1 (PARP1) in myelination and remyelination of the central nervous system (CNS) remains enigmatic. Here, we report that PARP1 is an intrinsic driver for oligodendroglial development and myelination. Genetic PARP1 depletion impairs the differentiation of oligodendrocyte progenitor cells (OPCs) into oligodendrocytes and impedes CNS myelination. Mechanistically, PARP1-mediated PARylation activity is not only necessary but also sufficient for OPC differentiation. At the molecular level, we identify the RNA-binding protein Myef2 as a PARylated target, which controls OPC differentiation through the PARylation-modulated derepression of myelin protein expression. Furthermore, PARP1’s enzymatic activity is necessary for oligodendrocyte and myelin regeneration after demyelination. Together, our findings suggest that PARP1-mediated PARylation activity may be a potential therapeutic target for promoting OPC differentiation and remyelination in neurological disorders characterized by arrested OPC differentiation and remyelination failure such as multiple sclerosis.

15 January 2021 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
PDF file
YZYanhong Zhang
Yanhong Zhang
NYNina Yin
Nina Yin
ASAnbang Sun
Anbang Sun
QWQifang Wu
Qifang Wu
WHWenzhu Hu
Wenzhu Hu
YLYanhong Liao
Yanhong Liao
Kidney fibrosis is generally confirmed to have a significant role in chronic kidney disease, resulting in end-stage kidney failure. Epithelial–mesenchymal transition (EMT) is an important molecular mechanism contributing to fibrosis. Tubular epithelial cells (TEC), the major component of kidney parenchyma, are vulnerable to different types of injuries and are a significant source of myofibroblast by EMT. Furthermore, TRPC6 knockout plays an anti-fibrotic role in ameliorating kidney damage. However, the relationship between TRPC6 and EMT is unknown. In this study, TRPC6−/−and wild-type (WT) mice were subjected to a unilateral ureteric obstruction (UUO) operation. Primary TEC were treated with TGF-β1. Western blot and immunofluorescence data showed that fibrotic injuries alleviated with the inhibition of EMT in TRPC6−/−mice compared to WT mice. The activation of AKT-mTOR and ERK1/2 pathways was down-regulated in the TRPC6−/−mice, while the loss of Na+/K+-ATPase and APQ1 was partially recovered. We conclude that TRPC6 knockout may ameliorate kidney fibrosis by inhibition of EMT through down-regulating the AKT-mTOR and ERK1/2 pathways. This could contribute to the development of effective therapeutic strategies on chronic kidney diseases.

1 July 2020 in Molecular Cancer Research
Verified
Journal Article
Closed access
PDF file
YZYanhong Zhang
Yanhong Zhang
Xiu Li FengXiu Li Feng
Xiu Li Feng
JZJin Zhang
Jin Zhang
JZJin Zhang
Jin Zhang
Iron regulatory protein 2 (IRP2) is a key regulator of iron homeostasis and is found to be altered in several types of human cancer. However, how IRP2 contributes to tumorigenesis remains to be elucidated. In this study, we sought to investigate the role of IRP2 in tumorigenesis and found that IRP2 promotes cell growth by repressing TAp63, a member of p53 tumor suppressor family. Specifically, we found that IRP2 overexpression decreased, whereas IRP2 deficiency increased, TAp63 expression. We also showed that the repression of TAp63 by IRP2 was independent of tumor suppressor p53. To uncover the molecular basis, we found that IRP2 stabilized TAp63 mRNA by binding to an iron response element in the 3′UTR of p63 mRNA. To determine the biological significance of this regulation, we showed that IRP2 facilitates cell proliferation, at least in part, via repressing TAp63 expression. Moreover, we found that IRP2 deficiency markedly alleviated cellular senescence in TAp63-deficient mouse embryo fibroblasts. Together, we have uncovered a novel regulation of TAp63 by IRP2 and our data suggest that IRP2 exerts its oncogenic activities at least in part by repressing TAp63 expression. Implications: We have revealed a novel regulation of TAp63 by IRP2 and our data suggest that IRP2 exerts its oncogenic activities, at least in part, by repressing TAp63 expression.

3 April 2023
Verified
Other
Open access
YZYanhong Zhang
Yanhong Zhang
Xiu Li FengXiu Li Feng
Xiu Li Feng
JZJin Zhang
Jin Zhang
JZJin Zhang
Jin Zhang
The oligos used for generation of sgRNA expression vectors

3 April 2023
Verified
Other
Open access
YZYanhong Zhang
Yanhong Zhang
Xiu Li FengXiu Li Feng
Xiu Li Feng
JZJin Zhang
Jin Zhang
JZJin Zhang
Jin Zhang
Iron regulatory protein 2 (IRP2) is a key regulator of iron homeostasis and is found to be altered in several types of human cancer. However, how IRP2 contributes to tumorigenesis remains to be elucidated. In this study, we sought to investigate the role of IRP2 in tumorigenesis and found that IRP2 promotes cell growth by repressing TAp63, a member of p53 tumor suppressor family. Specifically, we found that IRP2 overexpression decreased, whereas IRP2 deficiency increased, TAp63 expression. We also showed that the repression of TAp63 by IRP2 was independent of tumor suppressor p53. To uncover the molecular basis, we found that IRP2 stabilized TAp63 mRNA by binding to an iron response element in the 3′UTR of p63 mRNA. To determine the biological significance of this regulation, we showed that IRP2 facilitates cell proliferation, at least in part, via repressing TAp63 expression. Moreover, we found that IRP2 deficiency markedly alleviated cellular senescence in TAp63-deficient mouse embryo fibroblasts. Together, we have uncovered a novel regulation of TAp63 by IRP2 and our data suggest that IRP2 exerts its oncogenic activities at least in part by repressing TAp63 expression.Implications:We have revealed a novel regulation of TAp63 by IRP2 and our data suggest that IRP2 exerts its oncogenic activities, at least in part, by repressing TAp63 expression.

1 April 2021 in Cellular Signalling
Verified
Journal Article
Closed access
YZYanhong Zhang
Yanhong Zhang
SVSenthil K. Venogopal
Senthil K. Venogopal
SHSongquing He
Songquing He
PLPinggue Liu
Pinggue Liu
Jian WuJian Wu
Jian Wu
MZMark A. Zern
Mark A. Zern